Keywords: Bayer, Onyx, Nexavar, NSCLC, Phase III

Bayer/Onyx’s Nexavar disappoints as first-line advanced NSCLC therapy, failing to meet goals in Ph III study

Article | 14 June 2010

Print This

German drug major Bayer HealthCare and USA-based partner Onyx Pharmaceuticals revealed this morning that the final analysis of the Phase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in